Navigation Links
SuviCa Inc. of Boulder to commercialize CU-Boulder cancer screening technology
Date:9/19/2011

SuviCa Inc. of Boulder and the University of Colorado recently completed an exclusive license agreement for a CU drug screening technology to identify novel therapies for cancer.

The patented drug discovery tool, developed by CU-Boulder Associate Professor Tin Tin Su of the molecular, cellular and developmental biology department, uses a genetically modified Drosophila fruit fly model to screen for compounds effective against various types of cancer, either alone or in combination with existing therapies.

The screening technique will be used to identify new clinical candidates using a methodology that is both time efficient and cost-effective. Because it uses a whole-animal screening model, the technique can more easily eliminate drug candidates with undesired toxicity.

"SuviCa looks forward to advancing Dr. Su's technology in order to find better ways to treat cancer patients and to build a world-class business in the Front Range region," said Judy Hemberger, SuviCa's chairman and CEO.

"We are excited about the commercial possibilities for the drug screening technology developed by Dr. Su, which has already been used at CU to identify promising therapeutic candidates," said Tom Smerdon, director of licensing and new business development at the CU Technology Transfer Office, or TTO.

SuviCa recently received funding from Colorado's Bioscience Discovery Evaluation Grant Program, an initiative launched in 2007 by the state of Colorado's Office of Economic Development and International Trade to provide early-stage, matching seed grants to enable the development and commercial validation of promising technologies that are licensed from Colorado research institutions.

SuviCa also has received a grant from the Internal Revenue Service through the Qualifying Therapeutic Discovery Project Program aimed at small businesses. Current and future efforts will focus on identifying and optimizing additional lead compounds to enter into formal clinical testing.

SuviCa Inc. is an early-stage cancer drug discovery and development company co-founded by Su, who now serves as its chief science officer. Judith Hemberger, a former co-founder and COO of Boulder-based Pharmion, has joined the senior management team as chairman and CEO.

Working in close collaboration with scientists at CU-Boulder, the University of Colorado Anschutz Medical Campus and Colorado State University, SuviCa is pursuing a promising discovery process based on several small molecules initially identified using its proprietary screening technology and targeted to a distinct cellular process. SuviCa researchers hope to discover and develop novel drugs used as standalone therapies or to prevent tumor recurrence following treatment with a variety of approved anti-cancer therapies.

CU's TTO pursues, protects, packages and licenses to business the intellectual property generated from research at CU. The office provides assistance to faculty, staff and students, as well as to businesses looking to license or invest in CU technology.


'/>"/>

Contact: Lindsay Lennox
lindsay.lennox@cu.edu
303-735-5518
University of Colorado at Boulder
Source:Eurekalert

Related biology news :

1. CU-Boulder study suggests air quality regulations miss key pollutants
2. New CU-Boulder study shows diversity decreases chances of parasitic disease
3. Evolution education for K-12 teachers needs beefing up, says CU-Boulder professor
4. CU-Boulder study shows 53 million-year-old high Arctic mammals wintered in darkness
5. CU-Boulder study shows Maya intensively cultivated manioc 1,400 years ago
6. Noise pollution negatively affects woodland bird communities, says CU-Boulder study
7. Daily bathroom showers may deliver face full of pathogens, says CU-Boulder study
8. CU-Boulder team identifies DNA "barcodes to help track illegal trading of wildlife products
9. 3 payloads built by CU-Boulder set for launch on space shuttle Atlantis
10. Swan song of space shuttle Discovery to carry 2 payloads built by CU-Boulder
11. Final flight of space shuttle Discovery to carry 2 payloads built by CU-Boulder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology: